COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    pmm2-cdg
Previous Study | Return to List | Next Study

Natural History Study Protocol in PMM2-CDG (CDG-Ia)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03173300
Recruitment Status : Recruiting
First Posted : June 1, 2017
Last Update Posted : October 1, 2020
Information provided by (Responsible Party):
Glycomine, Inc.

Brief Summary:

Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG)

This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia).

Condition or disease
Phosphomannomutase 2 Deficiency

Detailed Description:

Subjects enrolled in this natural history study will be thoroughly examined for signs and symptoms of PMM2-CDG. Medical history, physical examination, laboratory testing and imaging studies will be performed during a single consultation. Follow-up will occur every 6 months at a minimum, depending on the standard of care at the investigator's institution as well as the clinical status of the individual patient. All medical procedures are routine. No new therapy is offered as part of this study, and no change in the patients' routine therapy is dictated by this protocol. No randomization will be performed.

All serious and non-serious adverse events will be recorded in the study CRF database.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical and Basic Investigations Into Phosphomannomutase Deficiency (PMM2-CDG)
Actual Study Start Date : January 8, 2018
Estimated Primary Completion Date : September 2024
Estimated Study Completion Date : December 2024

Primary Outcome Measures :
  1. collect clinical and biological information in patients with CDG-PMM2 [ Time Frame: up to 4 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with PMM2-CDG, all ages

Inclusion Criteria:

  • Informed consent/assent by the patient and/or their legally authorized representative
  • Confirmed diagnosis of PMM2-CDG, based on enzymatic or molecular tests
  • Willing and able to adhere to study requirements described in the protocol and consent/assent documents

Exclusion Criteria:

  • Known or suspected differential diagnosis of any other known CDG (not PMM2-CDG)
  • Currently using investigational drug
  • Blood loss of >250 mL or donated blood within 56 days, or donated plasma within 7 days, of study screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03173300

Layout table for location contacts
Contact: Horacio Plotkin, MD / Chief Medical Officer +1 (781) 290-3722

Layout table for location information
United States, Louisiana
Tulane University Medical Center Terminated
New Orleans, Louisiana, United States, 70112
United States, Minnesota
Mayo Clinic College of Medicine Recruiting
Rochester, Minnesota, United States, 55905
Contact: Sarah Bohlen, Study Coordinator    507-293-7485   
Contact: Eva Morava-Kozicz, MD, PhD    504-444-9386   
Principal Investigator: Marc Patterson, MD, PhD         
United States, Pennsylvania
Children's Hospital of Philadelphia (CHOP) Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Nia Nichols    267-426-0186   
Contact: Andrew Edmondson, MD, PhD    215-313-4607 ext 22178   
Principal Investigator: Can Ficicioglu, MD, PhD         
Children's Hospital of Pittsburgh Terminated
Pittsburgh, Pennsylvania, United States, 15224
United States, Washington
Seattle Children's Hospital Recruiting
Seattle, Washington, United States, 98105
Contact: Hayden Vreugdenhil    206-884-1264   
Contact: Christina Lam, MD   
Principal Investigator: Christina Lam, MD         
University Hospital Leuven Recruiting
Leuven, Belgium
Contact: Nele Vanhoutvin, Paramedisch coördinator Metabole Ziekten    +32 16 34 19 47   
Contact: Peter Witters, MD, PhD   
Principal Investigator: Peter Witters, MD, PhD         
General University Hospital in Prague Recruiting
Prague, Czechia
Contact: Anna Čechová, MD   
Contact: Tomas Honzik, MD, PhD   
Principal Investigator: Tomas Honzik, MD, PhD         
Necker Enfants-Malades Hospital Recruiting
Paris, France
Contact: Eric Bauchart, PhD   
Contact: Pascale de Lonlay, MD   
Principal Investigator: Pascale de Lonlay, MD         
University Hospital of Catania Recruiting
Catania, Italy
Contact: Rita Barone, MD, PhD   
Radboud University Nejmegen Medical Center Recruiting
Nijmegen, Netherlands
Contact: Mirian Janssen, MD PhD    +31 24 361 8819   
Mother and Child Institute (Instytut Matki i Dziecka) Not yet recruiting
Warsaw, Poland
Contact: Jolanta Sykut-Cegielska, MD, PhD         
Centro Hospitalar do Porto Not yet recruiting
Porto, Portugal
Contact: Dulce Quelhas, MD   
Hospital Sant Joan de Déu Recruiting
Barcelona, Spain
Contact: Mercedes Serrano, MD, PhD   
Sponsors and Collaborators
Glycomine, Inc.
Layout table for investigator information
Study Director: Horacio Plotkin, MD / Chief Medical Officer Glycomine, Inc.
Layout table for additonal information
Responsible Party: Glycomine, Inc. Identifier: NCT03173300    
Other Study ID Numbers: GLY-000
First Posted: June 1, 2017    Key Record Dates
Last Update Posted: October 1, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Glycomine, Inc.: